Didrocal

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Nopērc to tagad

Lejuplādēt Lietošanas instrukcija (PIL)
07-06-2024
Lejuplādēt Produkta apraksts (SPC)
07-06-2024

Aktīvā sastāvdaļa:

Calcium carbonate; Disodium etidronate

Pieejams no:

Pfizer Australia Pty Ltd

Klase:

Medicine Registered

Lietošanas instrukcija

                                DIDROCAL*
1
DIDROCAL*
_Disodium Etidronate & Calcium carbonate_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
PLEASE READ THIS LEAFLET CAREFULLY
BEFORE YOU START TAKING DIDROCAL.
This leaflet answers some common
questions about Didrocal.  It does not
contain all the available information
and it does not take the place of
talking to your doctor or pharmacist.
All medicines have risks and
benefits.  Your doctor has weighed
the risks of you taking Didrocal
against the expected benefits it will
have for you.
USE DIDROCAL AS INSTRUCTED AND
FOLLOW THE ADVICE GIVEN IN THIS
LEAFLET.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
This medicine is only available with
a doctor's prescription.
USE DIDROCAL AS DIRECTED BY YOUR
DOCTOR.
WHAT DIDROCAL IS USED
FOR
The Didrocal pack contains two
different tablets.
The white tablets contain the active
ingredient disodium etidronate.  It
belongs to a group of medicines
called bisphosphonates.
The blue tablets contain the active
ingredient calcium carbonate. These
tablets are a calcium supplement used
to increase the level of calcium in
your bones.
The combination of disodium
etidronate and calcium carbonate
tablets in Didrocal is used to treat
osteoporosis.
Osteoporosis is a term used to
describe a thinning and weakening of
bones. Early on, osteoporosis has no
symptoms. However, if left
 untreated it can result in broken
bones (fractures). Fractures may
occur during normal, everyday
activity, such as lifting, or from
minor injury that would not
ordinarily fracture a bone. Fractures
usually occur at the hip, spine or
wrist.
Didrocal works by increasing bone
mass, which helps to avoid bone
fracture.
Didrocal is also used to prevent bone
loss in people taking large doses of
corticosteroids. Corticosteroids are
medicines (e.g. prednisone,
dexamethasone) used to reduce
                                
                                Izlasiet visu dokumentu
                                
                            

Produkta apraksts

                                PRODUCT INFORMATION 
DIDROCAL
®
A Compliance Pack for Osteoporosis Therapy containing 28 tablets of
disodium etidronate 
200 mg and 76 tablets of calcium carbonate 1.25 g. 
NAME OF THE MEDICINE 
Non-proprietary name: 
DISODIUM ETIDRONATE 
Chemical name: 
Disodium dihyrogen (1-hydroxyethylidene) diphosphonate 
CAS No: 
7414-83-7 
ONa    OH    ONa 
 
 
 
 
 
 
HO         P        C        P        OH 
 
 
 
 
 
 
O       CH
3
    O 
 
 
Non-proprietary name: 
CALCIUM CARBONATE 
Chemical name: 
Calcium carbonate 
CAS No: 
471-34-1 
 
 
Version: pfpdidot10707 
Supersedes: pfpdidot11106 
Commercial/Non-Commercial 
Page 1 of 10 
DESCRIPTION 
Disodium etidronate, often referred to in the literature as EHDP or
disodium EHDP, is a white 
powder, highly soluble in water, with a molecular formular C
2
H
6
Na
2
O
7
P
2.  
The molecular 
weight is 250. 
It is supplied in rectangular white tablets containing 200 mg of
disodium etidronate for oral 
administration. 
The light blue calcium carbonate tablets are a conventional oral
formulation used as a 
supplement to dietary calcium for the formation of normal bone.
 Each tablet contains the 
equivalent of 500 mg of elemental calcium. 
PHARMACOLOGY 
Disodium etidronate acts primarily on bone.  It can modify the
crystal growth of calcium 
hydroxyapatite  _in vitro_ by chemisorption onto the crystal
surface.  Depending on 
concentration, the drug primarily inhibits either crystal resorption
or crystal growth.  The 
exact mechanism of _in vivo_ activity is uncertain and may
additionally involve direct effects on 
cellular metabolic processes. 
Serum phosphate elevations have been observed when
disodium etidronate is administered at 
daily doses of 10 mg/kg body weight/day or above and occasionally at
5 mg/kg/day.  This has 
not been found to be an indication for discontinuing therapy.  This
drug-related elevation 
appears to be the result of increased tub
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu

Skatīt dokumentu vēsturi